ProQR Therapeutics - Creating RNA therapies for patients in need

On a mission

At ProQR, we are passionate about pushing the boundaries of science and technology to create innovative solutions for unmet medical needs. Our team is dedicated to conducting cutting-edge research and development in the RNA editing field to improve the lives of patients and families affected by genetic disorders.

We believe that every person deserves access to the best possible care, and we are committed to working together as a community to make that happen. Join us on our mission to make a real difference in the lives of those we serve.

Outside the front of the ProQR office in Leiden

Our science

Axiomer technology - RNA base editing

Scientists at ProQR have invented a new way to use RNA oligonucleotides to alter RNA. The Axiomer® technology has the potential to become a new class of medicine and treat currently untreatable diseases.
How Axiomer and ADAR work

What is RNA and how can we use ADAR, the body’s own RNA editing machinery to treat disease? Check out our latest video explaining how it works.
Internal link Working at ProQR

Latest press releases

Internal link ProQR Announces Year End 2023 Operating and Financial Results
Date: 13 March 2024
Internal link ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
Date: 15 February 2024
Internal link ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
Date: 19 January 2024

Internal link More press releases

ProQR Community News

ProQR welcomes a new generation of scientists

Community news

Throughout the year ProQR regularly welcomes student groups from across the Netherlands.
Catching up with returning ProQRian René Beukema

Community news

In this personal interview, we speak to ProQR’s Chief Corporate Development Officer & General Counsel, René Beukema on his return to ProQR.
Exploring why companies partner their technology

Community news

Partnerships in our industry are very common as companies look to benefit from knowledge and resource sharing. In this blog we explore why companies, like ProQR, partner with other companies.

ProQR & Eli Lilly and Company partnership

Since 2021 ProQR has partnered with Eli Lilly and Company focusing on the discovery, development, and commercialization of potential new using ProQR’s proprietary Axiomer® RNA editing platform.

Internal link Read about our partnership

ProQR and Lilly logos and Axiomer technology image

Meet us at

Internal link Van Lanschot Kempen Life Sciences Conference

Investor conference

ProQR is participating in the Van Lanschot Kempen Life Sciences Conference.
- Add Van Lanschot Kempen Life Sciences Conference to calender
Investor
Apr 17 2024

Internal link More events